Qiagen N.V.
QGEN · NYSE · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 20-F · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Mar 2026
Headline figures
Qiagen N.V. at a glance
In FY2025, Qiagen N.V. reported revenue of USD 2,089,999 thousands, EBITDA of USD -68,448 thousands, EBITDA margin of -3.3%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 1,978,214 | 2,089,999 | |||
| EBITDA | -598,101 | -68,448 | |||
| EBITDA margin | -30.2% | -3.3% | |||
| Free cash flow | 506,377 | 453,277 | |||
| ROIC | -16.6% | -6.7% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas